Search results | monoclonal

Reports

Monoclonal Antibodies Partnering Terms and Agreements

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.

Cancer Monoclonal Antibody Partnering Terms and Agreements

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Cancer Diagnostics Partnering Terms and Agreements

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract documents Top cancer diagnostics deals by value   The more »

Antibody Partnering Terms & Agreements

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Monoclonal antibodies

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made…

PDL Biopharma: Capitalizing on the humanization of monoclonal antibodies

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology.

AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

Q2 Partnering and Licensing Pharma trends of 2014

July 2014 By Raveena Bhambra Q2 was full of deals, coupled with the talk of potential deals, and overall it finished on a high with a large volume of agreements coming together in June.

Seattle Genetics : Biotech industry partnering activity 2009-2014

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment.

Sun Pharmaceutical: Fast becoming the branded generic company of choice

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics.

Trends analysis: Cancer vaccine partnering on the rise

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena.

Events

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Deals

Celgene and Open Monoclonal Tech in OmniAb alliance

Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics

Licensing agreement for monoclonal antibodies

Visterra has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus.

Merck big pharma deals Xencor for monoclonal antibody licensing agreement

Xencor enters pharma deals with Merck for the licensing of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody to the big pharma company.

Pfizer signs a pharma licensing deal with Open Monoclonal Technology

Pfizer, the world’s largest pharmaceutical company collaborated with Open Monoclonal Technology by signing a  pharma licensing agreement with the latter to use OMT’s OmniRat for antibody research and development

Vivalis partners with Sanofi Pasteur for the discovery of human monoclonal antibodies against infectious diseases

Vivalis has announced the signature with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious disease targets.

Morphotek in licensing deal with Centocor Ortho Biotech for exclusive development and commercialization fights for therapeutic monoclonal antibody

Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Financial terms were not disclosed. Preclinical studies, conducted by Centocor Ortho Biotech, have shown that the relevant antigen is over-expressed in many solid tumors.

Series B financing for $90 million for Kymab

Kymab has successfully raised an additional US$50 million to complete a US$90 million Series B financing.

EMD Serono and Pfizer in co-promotion agreement for Xalkori

EMD Serono has begun co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.

Celgene and AstraZeneca in MEDI4736 pact

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies

Eli Lilly and Innovent in pact for three cancer treatments

Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company